(Q34426066)

2 August 2017

title

PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma (English)

1 reference

2 August 2017

0 references

1 reference

1 reference

Heather E Oakervee

1

1 reference

2 August 2017

Rakesh Popat

2

1 reference

2 August 2017

Nicola Curry

3

1 reference

2 August 2017

Pat Smith

4

1 reference

2 August 2017

Curly Morris

5

1 reference

2 August 2017

Mary Drake

6

1 reference

2 August 2017

Samir Agrawal

7

1 reference

2 August 2017

Jim Stec

8

1 reference

2 August 2017

David Schenkein

9

1 reference

2 August 2017

Dixie-Lee Esseltine

10

1 reference

2 August 2017

Jamie D Cavenagh

11

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 June 2005

1 reference

British Journal of Haematology

2 August 2017

published in

1 reference

2 August 2017

volume

129

1 reference

2 August 2017

issue

6

1 reference

2 August 2017

page(s)

755-762

1 reference

The proteasome: a suitable antineoplastic target

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05519.X

Single versus double autologous stem-cell transplantation for multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05519.X

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05519.X

Thalidomide in multiple myeloma: current status and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05519.X

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05519.X

The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05519.X

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05519.X

Advances in biology of multiple myeloma: clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05519.X

A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05519.X

Multiple myeloma: evolving genetic events and host interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05519.X

Management of multiple myeloma: a systematic review and critical appraisal of published studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05519.X

Proteasome inhibitors disrupt the unfolded protein response in myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05519.X

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05519.X

Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05519.X

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05519.X

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05519.X

Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05519.X

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05519.X

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05519.X

Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05519.X

Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05519.X

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05519.X

Diagnosis and management of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05519.X

Thalidomide alone or with dexamethasone for previously untreated multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05519.X

Impact of complete remission with intensive therapy in patients with responsive multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05519.X

10.1111/J.1365-2141.2005.05519.X

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference